Curis Surges 330% On Early Stage Blood Cancer Data
December 08, 2020 at 12:29 PM EST
Curis, Inc. shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leukemia and myelodysplastic syndromes.
